| Literature DB >> 33674766 |
Ping An1, Efe Sezgin2,3,4, Gregory D Kirk3,5, Priya Duggal3, Elizabeth Binns-Roemer2, George Nelson6, Sophie Limou2,7,8, Mark L Van Natta3, Douglas A Jabs3,9, Michelle Estrella10,11, Jeffrey B Kopp12, Cheryl A Winkler13.
Abstract
Apolipoprotein L1 (APOL1), an innate immune factor against African trypanosoma brucei, inhibits HIV-1 in vitro. The impact of APOL1 G1-G2 variants on HIV-1-associated opportunistic infections (OIs) is unknown. Here, we report findings from a metaanalysis of four HIV/AIDS prospective cohorts (ALIVE, LSOCA, MACS, and WIHS) including 2066 African American participants. Using a global test combining all four cohorts, carriage of two APOL1 variant alleles is associated with a 50% reduction in odds of OI (combined OR 0.50, 95% CI 0.33-0.76). Subgroup analysis of OI etiological categories (viral, parasitic, fungal and Mycobacterial) suggests the possibility of specific protection from fungal infections (OR 0.54. 95% CI 0.32-0.93; PBonferroni corrected = 0.08). We observe an association of APOL1 variant alleles with host protection against OI in HIV-positive individuals. The study suggests a broader role of APOL1 variant alleles in innate immunity in vivo.Entities:
Year: 2021 PMID： 33674766 PMCID： PMC7977062 DOI： 10.1038/s42003-021-01812-z
Source DB: PubMed Journal: Commun Biol ISSN： 2399-3642